Piper Sandler analysts said in a note Friday that the key perceived Eylea overhang for Regeneron (NASDAQ: REGN ) has diminished with the Mylan infringement judgement. Last year, REGN filed a patent infringement lawsuit against Viatris' Mylan unit, alleging that the regulatory filing of an aflibercept biosimilar for approval infringed on certain patents. This week, a court ruled that REGN's patent rights were infringed.